Sinovac Biotech (SVA) & Ocera Therapeutics (OCRX) Financial Survey

Sinovac Biotech (NASDAQ: SVA) and Ocera Therapeutics (NASDAQ:OCRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, institutional ownership, dividends, valuation and risk.

Profitability

This table compares Sinovac Biotech and Ocera Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sinovac Biotech N/A N/A N/A
Ocera Therapeutics N/A -383.51% -134.92%

Risk and Volatility

Sinovac Biotech has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Comparatively, Ocera Therapeutics has a beta of 2.46, meaning that its stock price is 146% more volatile than the S&P 500.

Valuation and Earnings

This table compares Sinovac Biotech and Ocera Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sinovac Biotech $72.43 million 6.41 -$590,000.00 ($0.01) -813.19
Ocera Therapeutics $610,000.00 77.79 -$26.89 million ($0.97) -1.85

Sinovac Biotech has higher revenue and earnings than Ocera Therapeutics. Sinovac Biotech is trading at a lower price-to-earnings ratio than Ocera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

32.5% of Sinovac Biotech shares are owned by institutional investors. Comparatively, 17.7% of Ocera Therapeutics shares are owned by institutional investors. 7.2% of Ocera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Sinovac Biotech and Ocera Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sinovac Biotech 0 0 0 0 N/A
Ocera Therapeutics 0 1 2 0 2.67

Ocera Therapeutics has a consensus target price of $5.25, suggesting a potential upside of 193.30%. Given Ocera Therapeutics’ higher probable upside, analysts plainly believe Ocera Therapeutics is more favorable than Sinovac Biotech.

Summary

Sinovac Biotech beats Ocera Therapeutics on 6 of the 11 factors compared between the two stocks.

Sinovac Biotech Company Profile

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company’s pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

Ocera Therapeutics Company Profile

Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.

Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply